OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain

An announcement from OKYO Pharma Limited Sponsored ADR ( (OKYO) ) is now available.

On May 1, 2025, OKYO Pharma Limited announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP). This designation is intended to expedite the development and review process for therapies addressing serious conditions with unmet medical needs, potentially accelerating the availability of new treatments. The Fast Track status allows for more frequent interactions with the FDA and eligibility for Accelerated Approval and Priority Review. OKYO Pharma’s CEO, Gary S. Jacob, expressed enthusiasm about this milestone, highlighting the company’s commitment to advancing urcosimod through clinical development and regulatory review to meet the significant unmet medical need in NCP treatment.

Spark’s Take on OKYO Stock

According to Spark, TipRanks’ AI Analyst, OKYO is a Underperform.

OKYO Pharma Limited’s stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.

To see Spark’s full report on OKYO stock, click here.

More about OKYO Pharma Limited Sponsored ADR

OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and dry eye disease. The company is listed on the NASDAQ Capital Market and is dedicated to discovering and developing novel molecules to address these ophthalmic conditions.

YTD Price Performance: 40.27%

Average Trading Volume: 103,065

Technical Sentiment Signal: Sell

Current Market Cap: $53.71M

Find detailed analytics on OKYO stock on TipRanks’ Stock Analysis page.